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INTRODUCTION
Hypertension is one of the most popular fields of research 
in modern medicine due to its high prevalence (around 30% 
worldwide), and its major impact on cardiovascular risk, such as 
myocardial infarction, stroke, or cardiovascular death [1]. On the 
other hand, an effective treatment of hypertension substantially 
reduces the risk of complications. 
Surprisingly, a considerable number of subjects with arterial 
hypertension remain untreated or uncontrolled despite a 
combination of antihypertensive drugs [2]. Resistant arterial 
hypertension is defined as blood pressure higher than 140/90 
mmHg despite adherence to at least three maximally tolerated 
doses of antihypertensive medications from complementary 
classes including a diuretic at an appropriate dose [3].
An important consideration in defining a patient with resistant 
hypertension is the mislabeling of secondary hypertension 
as resistant hypertension [4,5]. Secondary forms of arterial 
hypertension are not rare and are frequently associated with 
treatment resistance unless the etiological factor is removed. 
The list for secondary hypertension is long and includes a wide 
variety of conditions [5]. Special attention should be given to 
the most common causes of secondary hypertension: primary 
aldosteronism, renal parenchyma diseases, reno vascular 
diseases, adrenal pheochromocytoma, Cushing’s syndrome, and 
obstructive sleep apnea [6].
Here, we report a patient with resistant hypertension caused 
by multiple steno-occlusive arteries due to antiphospolipid 
syndrome (APS) and coexisting with sub-clinical Cushing’s 
syndrome. 
CASE REPORT
A 58-year-old woman with resistant hypertension, blood 
pressure (BP) of 220/110 mmHg despite therapy with four 
antihypertensive drugs (telmisartan, nebivolol, nifedipine, 
furosemide), post-prandial abdominal pain and left adrenal 
mass (3 cm) incidentally discovered (Figure 1), was referred to 
our Specialized Center of Secondary Hypertension, University 
of Rome “La Sapienza”, Rome, Italy. The patient underwent 
the established clinical and laboratory evaluation to identify 
essential hypertension and she did not have any secondary 
causes of hypertension.
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Abstract
Resistant hypertension is defined as above of blood pressure (≤ 140/90 mmHg) 
despite therapy with three or more antihypertensive drugs of different classes at 
maximum tolerable doses with one bling a diuretic.
An important consideration in defining a patient with resistant hypertension is the 
mislabeling of secondary hypertension as resistant hypertension.
Here, we report a patients with resistant hypertension caused by multiple steno-
occlusive arteries due to antiphospholipid syndrome and coexisting with subclinical 
Cushing’s syndrome. 
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Physical examination did not show the typical Cushingoid 
features such as central obesity, moon face, skin atrophy, purple 
striae and buffalo hump. Her average BP was 175/105 mmHg 
equal in both arms, and 24-h-ambulatory blood pressure (ABPM) 
was 140/90 mmHg with a non-dipping profile. Her height was 
165 cm, weight was 65 Kg, and body mass index (BMI) was 25.4 
Kg/m2. No cardiac murmurs or abdominal bruits were revealed. 
The ECG showed evidence of mild left ventricular hypertrophy 
on voltage criteria. The echocardiography confirmed mild 
ventricular concentric remodeling. Hypertensive retinopathy 
grade 2was found at fundus examination. 
General laboratory test did not reveal any remarkable 
abnormalities, except for mild elevation of serum creatinine 
to 1.16 mg/dl (normal value: 0.50-0.90 mg/dl), a reduction of 
serum potassium 3.3 mEq/l (normal value: 3.5-5 mEq/l), and 
microalbuminuria 100 mg/24h (normal value: < 30 mg/24h). 
The 24 hr creatinine clearance was 87 ml/min (normal value: 95-
140 ml/min). Examination of urine showed microematuria.
Renal ultrasonography including Doppler revealed that 
the right kidney longitudinal size was 11 cm while the left 
kidney longitudinal size measured 7 cm. Renal blood flows was 
decreased in the left kidney.
Renal scanning with [99m TC] diethylenetriaminepentaacetic 
acid (DTPA) showed lower uptake of the tracer in the left kidney 
than in the right, and the curve for the left kidney was flat after 
captopril administration. The scintigraphic images suggested the 
presence of stenosis of the left renal artery.
Table 1 shows the hormone test’s results. Plasma renin 
activity (PRA) (19.4 ng/ml/h; normal value 0.2-2.7 ng/ml/h) and 
plasma aldosterone (PAC) (16.5 ng/dl; normal value 3-16 ng/dl) 
levels were high. Morning cortisol (PC) levels (27 µg/dl; normal 
value 4.5-24 µg/dl) and urinary free cortisol excretion (UFC) 
(170 µg/24h) were high as well. PC levels were not suppressed 
after overnight dexamethasone suppression test (6.2µg/dl). 
Plasma ACTH was 9 pg/ml (normal value: 10-90 pg/ml). Urinary 
total metanephrines (30µg/24h) vanillic-mandelic acid (6 
mg/24h) excretions were within normal limits (normal values 
20-345 µg/24h and 1-13.6 mg/24h, respectively). These findings 
suggested autonomous secretion of cortisol from the left gland 
and hyperreninemic aldosteronism. Subsequently, an abdominal 
tomography (CT) with arterial phase was performed. It confirmed 
the left adrenal mass (30 x 20 cm of diameter) and revealed a 
thrombosis of the superior mesenteric artery, stenosis of left 
renal artery and stenosis of common iliac artery (Figure 2). No 
stenosis was found on the right renal artery. The imaging didn’t 
show evidences of inflammatory vasculitis. Further laboratory 
evaluation revealed positivity for lupus anticoagulant (LAC), 
prolonger partial time, anti-β2- glycoprotein I antibodies (382 
CU; normal value: 0 – 20 CU) while anticardiolipin antibodies 
(ACA IgG 2,6, ACA IgM 2.1, respectively; normal value 0 – 20 CU), 
anti-ds-DNA and anti-neutrophil cytoplasmatic antibodies were 
not found. More parameter of hyper coagulability was within 
normal range. Antiphospolipid syndrome (APS) was supposed. 
Angioplasty and stenting was performed for the stenosis of the 
superior mesenteric artery, left renal artery and common iliac 
artery. The procedure has been successfully performed and the 
abdominal pain vanished with amelioration of BP and general 
conditions. The patient was treated with vitamin k-antagonist 
(VKA: warfarin) keeping international normalized ratio (INR) 
about 3. Lupus anticoagulant was also positive after 12 weeks, 
confirming the diagnosis of APS.
Six months later, the follow up visit revealed poor blood 
pressure control (BP 150/100 mmHg) despite antihypertensive 
treatment (telmisartan, nebivolol, furosemide) and the ABPM 
showed moderate hypertension with non-dipping profile. The 
hormone tests were performed again. In particular, UFC was 270 
µg /24h and the early morning plasma concentration of ACTH 
was 10.2 pg/ml, while PC was 23 µg /dl. In the dexamethasone 
(1 mg) suppression test, ACTH was suppressed less than 8.2 pg/
ml, whereas PC level decreased 6 µg /dl, confirming insufficient 
suppression of cortisol secretion. An adrenocortical scintigraphy 
using 131-I-methyl-norcholesterol showed significant uptake 
of radiotracer in left adrenal gland, concordant with adrenal 
mass (Figure 2). Subclinical Cushing’s syndrome due to an 
inappropriate cortisol secretion by left adrenal lesion was 
diagnosed. One month later, laparoscopic left adrenalectomy 
was performed. Pre-operative control of BP (140/90 mmHg) 
Figure 1 Abdominal RMN: left adrenal mass with diameter size of 3 
cm. 
At dia-
gnosis
Follow-
up range
Serum
Plasma renin activity (PRA)
Plasma aldosterone (PAC)
Plasma cortisol (PC)
ACTH
PAC/PRA
19.4
16.5
22.0
9
0.85
19.0
18.9
23
10
0.99
0.2-2.7 ng/
ml/h
3.0-16.0 ng/dl
4.5-21 µg/dl
10-90 pg/ml
< 40 ng/
ml/h:ng/dl
Urine
Free cortisol (UFC)
Aldosterone (AUR)Total metanephrines
Vanillil mandelic Acid
170
23
30
6
270.5
26
62
7
30-100 
µg/24h
2.8-34 µg/24h
20-345 
µg/24h
< 13 mg/24h
Desametasone sopprimer test (1 
mg/23h)
PC 6.2 6.0 < 1.8 µg/dl
Table 1: Data of the hormone tests.
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was achieved with oral nifedipine 60 mg, telmisartan 80 mg and 
spironolactone 25 mg. After adrenalectomy, a nodule of 2.5 cm 
size was removed. Microscopic examination revealed no area 
of capsule or blood vessel invasion, consistent with a benign 
adrenocortical adenoma. 
Post-operative Glucocorticoid therapy consisted of parenteral 
hydrocortisonhemisuccinate (200 mg to 30 mg/day) for six days 
and oral hydrocortisone 20 mg, decreased to 10 mg after the 
operation. After two months, UFC, PC and ACTH concentrations 
were within normal range (90.3µg/24h; 15µg/die and 22pg/ml 
respectively). Duplex ultrasound evidenced elevated velocities 
within the left renal artery.
DISCUSSION
In several epidemiological studies, the prevalence of arterial 
hypertension has been documented with worldwide prevalence 
of 30% [1]. Essential hypertension is a term applying to cases in 
which no causes can be identified and accounts for approximately 
85% of cases [7].
Secondary forms of hypertension are not rare and are 
frequently associated with treatment resistance unless the 
etiological factor is removed [8]. In this paper, we report a case 
of patient referred in our Center for resistant hypertension and 
adrenal incidentalomas. Subclinical Cushing’s syndrome due to 
left adrenal adenoma associated with multiple steno-obstructive 
vascular lesions (comprised left renal artery stenosis) and APS 
was diagnosed basing on clinical laboratory hormonal tests and 
imaging studies. In our clinical case the arterial hypertension was 
considered to be resistant because the patient had been unable 
to reach his BP goal (≤ 140/90 mmHg) despite of 4 appropriate 
medications. In fact, resistant hypertension is defined as above 
goal BP despite therapy with three or more antihypertensive 
medications of different classes at maximum tolerable does with 
one being a diuretic [3]. Prevalence of resistant hypertension 
is 10% within the hypertensive population [9], and should be 
considered after excluding pseudo-hypertension and secondary 
causes of hypertension as primary aldosteronism, renovascular 
hypertension, Cushing’s syndrome and pheochromocytoma.
In particular, guidelines for the management of hypertension 
recommended performing further examinations such has normal 
tests and renography if a clinical feature suggests secondary 
hypertension among hypertensive [10].
In our case, the resistant hypertension is secondary 
to the multiple artery stenosis due to APS coexisting with 
hypercortisolism (subclinical Cushing’s syndrome). APS 
is defined by the combination of venous arterial occlusive 
events, predominantly a thrombotic condition, accompanied 
by thrombocytopenia, in the presence of anti phospholipid 
antibodies [11-13]. The absence of any connective tissue disease 
is a characteristic of the primary form of the syndrome.
Major thrombotic events occur in the deep venous system, 
and the arterial occlusion is more frequently and predominates in 
the central territory [14]. Moreover, the thrombosis may develop 
anywhere in the renal vein and arteries [15]. Physiopathology 
of stenosis in APS remains unclear, but some investigators 
suggested arterial wall thrombosis, accelerated atherosclerosis, 
and/or proliferation of smooth muscle cells.
In particular, some data suggest that antiphospolipid 
antibodies have an effect on the initiation of endothelial cell lesions 
that characterize arteriosclerosis [16]. In fact, antiphospolipid 
antibodies have been shown to have atherogenesis properties, 
because they can cross-react with oxidized low density 
lipoprotein (OX-LDL) and may activated the endothelium system, 
a potent vasoconstrictor peptide [17]. In our patient we found 
many steno-obstructive disorders in abdominal vascularization 
and in particular in the left renal artery. Sangle et al [18] have 
demonstrated a significantly higher prevalence of renal artery 
stenosis (26%) in patients with APS who have difficult control 
hypertension, than in a hypertensive group, and suggested that 
renal artery stenosis may be an important cause of hypertension 
in APS.
Approximately, 70 percent of adrenal incidentalomas 
discovered in patients without extra-adrenal malignancy are 
benign adrenocortical adenoma [19-20].
Several studies have shown that a subset of these tumors 
secrete a mild excess of cortisol leading to the concept of 
“subclinical cortisol-secreting adenomas” [21]. Depending on the 
diagnostic criteria and the study design used, subclinical Cushing’s 
syndrome is found in 5% to 20 % of patients with adrenal 
incidentalomas [22]. Several studies have reported increasing 
evidence that subtle cortisol production and abnormalities in 
the hypothalamic-pituitary-adrenal axis are more frequent than 
previously thought. 
Barzon et al [23] found the estimated cumulative risk to 
develop overt Cushing’s syndrome of 12.5% after one year 
when considering only patients with subclinical autonomous 
glucorticoid over- production. Recent evidence suggests that 
subclinical Cushing’s syndrome might be associated with 
increased risk for arterial hypertension, diabetes, or osteoporosis 
[24]. In particular, the prevalence of hypertension in patients 
with endogenous hypercortisolism is approximately 80%, and 
the majority of patients present mild to moderate hypertension, 
whereas 17% could present severe form. Moreover, the 
hypertension is characterized by dysregulation of the BP 
circadian rhythm, with loss of the physiological nocturnal fall 
[24,25]. Our patient has a severe form hypertension with no-
dipping profile at ABPM. 
The mechanism of Glucocorticoid-induced hypertension 
Figure 2 Angio TC abdomen: stenosis of left renal artery. 
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and resistant hypertension was been largely elucidated: 1) 
activation of the renin-angiotensin system; 2) enhancement of 
cardiovascular reactivity to vasoconstrictors (catecholamine, 
endothelin, vasopressin and angiotensin II); 3) increased beta-
adrenergic receptor sensitivity to catecholamine; 4) suppression 
of the vasodilatatory systems (NO synthase, prostacyclin and 
kinin-kallickrein); 5) increased cardiac output, total peripheral 
resistance and renovascular resistance [24]- 
The hypertension in patients with endogenous 
hypercortisolism is significantly correlated with the duration 
of disease, and optimal treatment is the correction of the 
hypercortisolism without permanent dependence of hormone 
replacement.
In conclusion, we report the case of patient with resistant 
hypertension caused by multiple steno-occlusive arteries due to 
APS and coexisting with subclinical Cushing’s syndrome. BP falls 
is related to both dilatation of renal artery stenosis and removal 
of the cortisol-adrenal adenoma, so that antihypertensive therapy 
was successfully reduced, but not completely stopped. Probably, 
stable renal dysfunction occurred from too much time prior our 
specific treatment, preventing the complete normalization of 
blood pressure.
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